Milestone Pharmaceuticals Inc. MIST
Biotechnology: Pharmaceutical Preparations · IPO 2019 · data as of November 13, 2026
Milestone Pharmaceuticals Inc. (MIST) is a healthcare company listed in the US with a market value of about $65M.
Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -53%.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2019. It was profitable in 0 of the last 8 years in our data. Its share count rose by 99% over three years (dilution for shareholders).
Score: 0.2 / 5
Checks passed
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Net income | -$63M | -$42M | -$60M | -$58M | -$43M | -$50M | -$55M | -$23M |
| Free cash flow | -$49M | -$29M | -$47M | -$53M | — | — | -$52M | -$21M |
| EPS (diluted) | $-0.75 | $-0.67 | $-1.39 | $-1.38 | $-1.02 | $-1.70 | $-3.50 | $72.63 |
| Net margin | — | — | — | — | — | — | — | — |
| ROIC | -49.0% | -48.9% | -70.4% | -68.5% | -30.0% | -35.2% | -50.1% | -22.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $4.57, 779% above the current price; targets range from $1.00 to $8.00; the consensus rating is “Strong buy”; expected EPS is $-0.78 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Milestone Pharmaceuticals pay a dividend?
Not currently.
Is Milestone Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Milestone Pharmaceuticals scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.